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Background: The use of oral flutamide is rarely investigated in acne therapy. The aim of 
this study was to compare the efficacy of oral flutamide with that of a cyproterone-estradiol 
combination in treating acne lesions.
Methods: A randomized clinical trial enrolled patients with moderate acne into two equal 
groups to receive either oral flutamide or the cyproterone-estradiol combination for 6 months. 
Lesion count, Acne Severity Index, and Global Acne Grading system (GAGS) scores were 
used to assess improvement in acne lesions. The dichotomous measurement scale for primary 
endpoint assessment was defined as improvement from moderate to mild acne based on GAGS 
score. Patient satisfaction and dermal fat were also assessed. Intention to treat and per protocol 
analyses were done, reporting related effect sizes.
Results: Both treatments resulted in substantial improvement in acne lesions. Although flutamide 
seemed to have higher efficacy, an intention to treat analysis did not find the two treatment 
protocols to be different. The relative risk in intention to treat analysis was 1.8 (95% confidence 
interval [CI] 0.89–1.6), and was 1.33 (95% CI 1.03–1.72) for the per protocol analysis. The 
number needed to treat for flutamide compared with the cyproterone-estradiol combination was 
7.7 and 4.2 in the intention to treat and per protocol analyses, respectively.
Conclusion: Flutamide appears to be more effective than a cyproterone-estradiol combination 
in some aspects of acne treatment, but this requires confirmation in a larger trial.
Keywords: acne vulgaris, flutamide, cyproterone acetate, ethinyl estradiol, androgen 
antagonists
Introduction
Acne is attributed to many factors, including increased sebum production, altered quality 
of sebum lipids, regulation of cutaneous steroidogenesis, androgen activity, interac-
tion with neuropeptides, proinflammatory and anti-inflammatory processes, follicular 
hyperkeratinization, and proliferation of Propionibacterium acnes within the follicle.1 
A recent review of acne therapy encourages research into nonantibiotic therapies to mini-
mize the risk of antibiotic resistance in the community.2 Recent research findings have 
highlighted the important role of hormones in the pathogenesis of acne. Androgens are 
believed to contribute to the development of acne, and this theory strengthens more when 
considering the interactions between sebum production, hirsutism, polycystic ovarian 
disease, and melasma with acne and androgens.3–7 Considering the pathophysiology of 
acne, newer steroid-related therapies need to be identified and investigated.  Cyproterone 
and oral contraceptives are recommended for treatment of acne in the literature but 
are discouraged for long-term use.8,9 However, use of oral flutamide has rarely been 
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 investigated in acne therapy. Flutamide is a  nonsteroidal 
peripheral androgen antagonist usually used to treat prostatic 
cancer. It lacks any progestogenic or antigonadotropic activ-
ity, and thus does not cause menstrual irregularity.10 The aim 
of this study was to compare the efficacy of oral flutamide with 
that of a cyproterone acetate-ethinyl estradiol combination in 
treating acne lesions.
Methods
This research was conducted in a specialty dermatology 
clinic during 2007–2008 as a randomized clinical trial with 
two parallel drug treatment arms. Females with moderate 
acne based on the Acne Severity Index (ASI) comprised the 
study population. The inclusion criteria were a complaint 
of moderate acne and age over 16 years. Exclusion criteria 
were pregnancy, lactation, hepatic disease, and use of oral 
contraceptives or androgenic drugs. Considering the paucity 
of information regarding the use of flutamide and its dosing, 
the study was conducted as a pilot investigation with a sub-
stantially small sample size, mainly due to ethical limitations 
and also due to practicability issues.
randomization and blinding
Randomization lists were generated to allocate the subjects 
into two treatment groups. The evaluating physician was 
blinded to treatment type. A nurse coordinated the evalua-
tion sessions, and was responsible for keeping the allocation 
codes, inviting the patients for each follow-up, coordinating 
physician visits, issuing blank evaluation forms, and collect-
ing the forms to be filed. She also checked whether the patient 
had used the prescribed drug during each treatment period. 
The physician responsible for evaluation was asked to docu-
ment whether unmasking had happened during evaluation or 
not. No unmasking occurred during the study.
Treatment protocol
The treatment regimen was continued for six months. The 
protocol in the first arm of the trial included flutamide 250 mg 
daily (21 days in each month) and topical clindamycin 1% 
for 6 months. The protocol in the second arm included a 
cyproterone compound containing 2 mg cyproterone and 
50 µg ethinyl estradiol (21 days in each month) plus topical 
clindamycin 1% for 6 months.
Outcome
Improvement of acne lesions and greasy skin were assessed 
every 2 months using a Mexameter®. The  Mexameter  determines 
an index for melanin and erythema, the main color  giving the 
parameters of the skin very accurately. Lesion count, ASI, and 
Global Acne Grading system (GAGS) scores were used to 
assess improvement of acne lesions.11 The formula used to cal-
culate ASI was 2 ×  pustules + 1 ×  papules +  comedones × 25%. 
Patient satisfaction regarding different aspects of acne treat-
ment was also assessed.
statistical analysis
Data were analyzed using the STATA 11 statistical soft-
ware package (STATA Corporation, College Station, TX). 
Descriptive and bivariate statistical methods were used for 
background data analysis. Classical risk assessment methods 
used in clinical trials as well as regression methods were 
employed to compare drug efficacy regarding the primary 
endpoints. Statistical test results were assessed using a 
two-sided hypothesis testing strategy, and P , 0.05 was 
considered to be statistically significant.
The GAGS score-based endpoint was defined on both 
continuous and dichotomous scales. Considering the repeated 
measurement nature of the data as well as missing values, 
a generalized estimation equation regression analysis was 
applied to assess outcome trends and adjust for possible 
confounders.12 The dichotomous measurement scale for pri-
mary endpoint assessment was defined as improvement from 
moderate to mild acne based on GAGS score. Relative risk, 
absolute risk difference, and number needed to treat statistics 
were calculated to compare the efficacy of flutamide with 
that of the cyproterone-estradiol combination. Continuous 
ASI and GAGS scores, as well as patient satisfaction, were 
considered as secondary endpoints.
Regarding the intention to treat analysis for missing out-
comes, although generalized estimation equations can handle 
missing data reasonably, considering the strong assumption 
of the statistical methods when handling missing data, a logi-
cal outcome permutation method was used in the intention 
to treat analysis to compare drug efficacy after 6 months of 
treatment. Cases with fewer than two measurement occa-
sions, a less than 50% decrease in lesion count (simultane-
ously for all three types of lesions), and cases with at least a 
50% decrease in lesions but without a continuing decrement 
trend over the first three measurements, were considered as 
treatment failures at last measurement. Results of the inten-
tion to treat analysis were compared with those of the per 
protocol analysis. Nonadherers were eliminated from the per 
protocol analysis. The main conclusion about the efficacy of 
the investigational treatment was based on the intention to 
treat analysis. A flow diagram of enrolment and follow-up 
in the study is given in Figure 1. The study was approved by 
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the ethics committee of the Ardabil University of Medical 
Sciences. The study aim was explained to eligible patients 
and informed consent was obtained. The study was registered 
with a clinical trial registry center approved by the World 
Health Organization.
Results
One patient in each group did not attend the first follow-up 
after receiving their allocated treatment. Twenty-four patients 
in the flutamide group and 25 patients in the cyproterone-
estradiol combination group completed the six-month 
follow-up period. Thirteen patients were lost to follow-up 
before 6 months (six from the cyproterone-estradiol com-
bination group and seven from the flutamide group). Ten 
of these lost cases had improved from moderate acne to a 
mild or lower GAGS score during the first three months of 
treatment. One of the 13 patients in the cyproterone-estradiol 
combination group had aggravation of acne one month after 
treatment and stopped follow-up. Two patients from the flut-
amide group who had at least a 70% decrement in number of 
comedones, papules, and pustules one month after treatment 
also stopped follow-up.
The mean age of the patients was 22 years. The patients 
had had acne on average for 3 years before enrollment. 
Thirty-seven percent reported a previous history of ovarian 
cysts. Half of the patients had a positive family history of 
acne in their sisters, 40% in their brothers, and less than 10% 
in their parents. Fifty-seven percent had previously received 
acne treatment, more than 90% of whom had received both 
topical and oral treatments. Topical clindamycin had been 
used by 45% of patients before. One patient had used eryth-
romycin and no patient mentioned using retinoic acid or 
benzoyl peroxide. No case of pregnancy or abortion occurred 
during this trial.
In a descriptive sense, as shown in Figure 2, the ASI 
and GAGS scores showed a trend of improvement in the 
flutamide group versus the cyproterone-estradiol combi-
nation group. The amount of sebum showed a decreasing 
trend overall (within-group P , 0.001) and prominently for 
the flutamide group (β = −4.3; between-group P , 0.01). 
Comedone, papule, and pustule counts showed a decreasing 
trend overall and on each measurement occasion (P , 0.001). 
Although the count of all three types of lesions showed a 
Eligible subjects enrolled
N = 64
Randomization
Control group 
N = 32
Flutamide group 
N = 32
Lost to follow-up after 
baseline N = 1
Lost to follow-up
after baseline N = 1
Patients with complete 
follow-up to six months 
N = 25
Patients with complete
follow-up to six months
 N = 24
ITT analysis N = 62
Per-protocol analysis N = 49
Figure 1 Flow diagram of trial enrolment and follow-up.
Abbreviation: ITT, intention to treat.
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Figure 2 Error bar graph of improvement trend of ASI and GAGS score compared between flutamide and cyproterone combination. 
Abbreviations: AsI, Acne Severity Index; CYP, cyproterone; GAGS, Global Acne Grading System; CI, confidence interval.
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Table 1 Comparing the efficacy of flutamide versus cyproterone in both per protocol and intention to treat analyses
Risk statistic Intention to treat analysis Per protocol analysis
Value 95% CI CSP Value 95% CI CSP
relative risk 1.18 0.89–1.6 0.25 1.33 1.03–1.72 0.02
risk difference 13% −10.0–33.0 24% 5–43
number needed to treat 7.7 – 4.2 2.3–20
Abbreviations: CI, confidence intervals; CSP, Chi-squared P value.
steeper decrement trend for flutamide, the difference was 
not found to be statistically significant.
The ASI decreased significantly over time in both groups 
(P , 0.001). It decreased more in the flutamide group, but 
the observed difference was not found to be statistically sig-
nificant (β = −4.3; P = 0.15). GAGS score decreased signifi-
cantly over time in both groups (P , 0.001). The decrement 
trend was more prominent for the flutamide group (β = −1.2; 
P , 0.001). After 6 months of treatment, 96% of subjects in 
the flutamide group versus 72% in the cyproterone-estradiol 
combination group improved, shifting down to mild acne 
from their moderate acne when they were enrolled into the 
study (P , 0.05). Comparison of dichotomous primary end-
point statistics for drug efficacy in both the per protocol and 
intention to treat analyses are reported in Table 1.
Satisfaction regarding different aspects of drug efficacy 
and tolerability was not found to be significantly different 
between the trial groups except for improvement in greasy 
skin (P , 0.05). Drug side effects were few, and there were 
no statistically significant differences between groups for 
tolerability. Minor scalp and face peeling, angular cheilosis, 
and mild gastrointestinal side effects were observed. One 
case of vague chest pain was also reported.
Discussion
Topical and oral antiandrogens have been recommended for 
use in the treatment of acne. Cyproterone acetate and newer 
cyclic oral contraceptives with strong antiandrogenic activity 
can be considered in this regard.1,10,13–15 Flutamide is quite 
new in acne research. For acne associated with polycystic 
ovary syndrome, a combination of flutamide and the oral 
contraceptive pill was found to be beneficial in a randomized 
control of 119 women followed up for 12 months.16 In the 
present study, although flutamide in the per protocol analysis 
appeared to be more effective than the cyproterone-estradiol 
combination, considering the substantial number of subjects 
lost to follow-up and also the limited information available 
for flutamide in dermatology research, we had to rely more 
on the intention to treat analysis results, which suggest simi-
lar efficacy. However, considering all trends and descriptive 
statistics in this study and taking into account the small size 
of our trial, we conclude conservatively that flutamide is at 
least as effective than cyproterone for treatment of moderate 
acne, but this needs to be tested in larger studies. Combining 
flutamide with oral contraceptives may help in reducing the 
flutamide dose in future trials.
Conclusion
Flutamide appeared to be at least as effective as the cyproter-
one-estradiol combination in some aspects of acne  treatment. 
However, this requires confirmation in a larger trial. A limita-
tion of the study was its rather small sample size, so it must 
be considered as a pilot study. However, from an ethical 
point of view, this is usually the case for preliminary clini-
cal trials in new drug indications. The second limitation was 
regarding the number of cases lost to follow-up. Although 
we tried to accommodate this during the statistical analysis, 
we need to be cautious about drawing a strong conclusion. 
The main strength of the study was its novelty in present-
ing a new treatment modality for moderate acne as well as 
a detailed analysis of the results using a suitable statistical 
methodology.
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